Mamantia, Rejane .

HRN: 23-58-04  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/21/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
08/21/2023
08/28/2023
IV
18mg
Q24h
Preterm, Potentially Septic
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Bloodstream    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: